Valuation: Shield Therapeutics plc

Market Cap 5.19Cr 6.86Cr 6.03Cr 5.68Cr 9.7Cr 657.81Cr 9.78Cr 68Cr 26Cr 335.66Cr 26Cr 25Cr 1.09TCr P/E 2026 *
323x
P/E 2027 * 6.54x
Enterprise Value 7.03Cr 9.3Cr 8.17Cr 7.7Cr 13Cr 891.73Cr 13Cr 92Cr 36Cr 455.02Cr 35Cr 34Cr 1.48TCr EV / Sales 2026 *
1.32x
EV / Sales 2027 * 1x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day+21.59%
1 month+21.59%
3 months+7.00%
6 months-39.42%
Current year-41.37%
1 month 0.09
Extreme 0.0856
0.09
Current year 0.05
Extreme 0.0521
0.17
1 year 0.05
Extreme 0.0521
0.17
3 years 0.01
Extreme 0.0135
0.17
5 years 0.01
Extreme 0.0135
0.6
10 years 0.01
Extreme 0.0135
2.45
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+21.59%-.--% - - 6.88Cr
-0.72%+2.76%+40.17%-3.49% 8.01TCr
+6.98%+33.79%+655.41%+94.84% 7.27TCr
-0.07%+2.70%-10.41%-28.96% 6.05TCr
-1.80%-3.05%-14.24%+26.38% 4.62TCr
+0.14%+2.81%+3.67%+158.04% 4.6TCr
-0.51%+4.79%+62.49%-12.15% 3.36TCr
-0.16%-0.25%+47.20%+114.18% 2.53TCr
-3.48%+6.06%+6.80%+166.49% 2.3TCr
-0.82%-0.77%+56.61%+98.36% 1.54TCr
Average +1.42%+5.23%+94.19%+68.19% 4.47TCr
Weighted average by Cap. -0.62%+6.70%+134.27%+52.56%

Financials

2026 *2027 *
Net sales 5.35Cr 7.07Cr 6.21Cr 5.85Cr 9.99Cr 677.99Cr 10Cr 70Cr 27Cr 345.96Cr 27Cr 26Cr 1.12TCr 6.99Cr 9.24Cr 8.12Cr 7.65Cr 13Cr 886.33Cr 13Cr 92Cr 35Cr 452.27Cr 35Cr 34Cr 1.47TCr
Net income 3L 3L 3L 3L 5L 3.27Cr 5L 33.81L 13.03L 1.67Cr 12.79L 12.52L 5.41Cr 77.44L 1.02Cr 89.91L 84.73L 1.45Cr 98Cr 1.46Cr 10Cr 3.91Cr 50Cr 3.84Cr 3.76Cr 162.49Cr
Net Debt 1.85Cr 2.44Cr 2.14Cr 2.02Cr 3.45Cr 233.92Cr 3.48Cr 24Cr 9.32Cr 119.36Cr 9.15Cr 8.96Cr 387.21Cr 1.8Cr 2.38Cr 2.09Cr 1.97Cr 3.36Cr 228.15Cr 3.39Cr 24Cr 9.09Cr 116.42Cr 8.92Cr 8.73Cr 377.67Cr
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0485GBP
Average target price
0.1667GBP
Spread / Average Target
+243.65%

Annual profits - Rate of surprise